Do Corporate Alliances Affect Biotechs' Market Performance?
Executive Summary
Is there a positive correlation between the number of corporate alliances biotechs have signed and their success at maintaining, or growing, their market valuations since their IPOs? To find out, we took the forty largest biotech IPOs completed in 1996 and 1997 and plotted their recent market valuations and percentage gain or loss over their IPO valuations against the number of significant corporate outlicensings they had signed since IPO.